Community Research and Development Information Service - CORDIS

H2020

Smartscope-X Report Summary

Project ID: 778089

Periodic Reporting for period 1 - Smartscope-X (Affordable, accessible and automatic screening solution for diabetic retinopathy)

Reporting period: 2017-08-01 to 2018-07-31

Summary of the context and overall objectives of the project

Smartscope-X project aims to develop, validate and commercialize revolutionary solution for screening of diabetic retinopathy and other blinding eye diseases. Solution combines a new low cost and customized hand held fundus camera connected with AI for automated diagnosis.

Almost 500 million people live with Diabetes. And diabetic retinopathy is one of the leading causes, and the fastest growing reason, of blindness. About 35% of all diabetics will at some point of their lives suffer vision loss because of this disease. However, progression of disease (diabetic retinopathy) and following vision loss can be prevented if the disease is detected at early stage. Annual retinal checks (screenings) are mandatory for everyone with diabetes. However current retinal imaging machines (fundus cameras) are expensive and there are not even enough eye doctors in the world to provide these screenings for everyone who are at risk. This makes screenings currently expensive and available only for small percent of all diabetics. Therefore, low cost hand held fundus cameras, connected to AI for easy screening and instant automatic diagnosis are urgently needed to prevent millions of people from going blind each year because of diabetic retinopathy.

The overall objectives are to develop customized camera that is connected to cloud solution with AI algorithms for automatic diagnosis based on captured images, to validate the solution via clinical trials and commercial pilots and to introduce commercial solution to the market.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

Camera development is in final stages currently and cloud solution development is ongoing.

AI algorithm partners have been identified and selected. Therefore, solution development and integration work is ongoing.

Validation plan, including clinical trials and commercial pilots, has been done and some initial tests have already been started. In addition, commercial plan has been made and channel / commercialization partner search is ongoing. Several partner meetings in key markets have been taken, piloting plan and initial business model has been created with them.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

By end of the project, it is expected that Optomed has the best proven solution to automatically and instantly screen diabetic retinopathy with a hand held fundus camera that is connected to AI. This will have following benefits:
i. Cost for society for arranging diabetic retinopathy screenings can potentially be reduced by factor of 10.
ii. Annual eye screenings can potentially reach all people in the world (500 million diabetics) within a next 10-20 years (currently screenings can reach only low percentage of people).
iii. Blindness and deaths because of diabetic retinopathy will radically drop from millions in each year (situation today) to a fraction of that.
iv. Via this pioneering project, Optomed has already significantly accelerated low cost hand held fundus camera technology development, and AI introduction in ophthalmology/healthcare. This will have significant positive impact in lives of millions of people in following years.

Related information

Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top